Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics reported a Q2 2026 net loss of $25.8 million, with R&D expenses of $21.2 million (down from $22.9 million a year earlier) and G&A of $4.6 million (up from $2.8 million); the clinical-stage company recorded no revenue. Its August 2026 upsized IPO, including full exercise of the underwriters' option, raised gross proceeds of $397.4 million, and combined with $55.0 million of existing cash as of June 30, management projects the balance sheet funds operations into 2029.
Key figures
- Net loss
- $25.8 million
- Ga expense
- $4.6 million
- Rd expense
- $21.2 million
- Cash runway
- into 2029
- Cash position
- $55.0 million
- Ipo gross proceeds
- $397.4 million
- Stockholders deficit
- $(276,080) thousand
- Ga expense prior year
- $2.8 million
- Rd expense prior year
- $22.9 million
- Ltg321 phase2 patients
- 120
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.